MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Neuroderm Ltd Company Profile (NASDAQ:NDRM)

Consensus Ratings for Neuroderm Ltd (NASDAQ:NDRM) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $26.88 (70.96% upside)

Analysts' Ratings History for Neuroderm Ltd (NASDAQ:NDRM)
Show:
DateFirmActionRatingPrice TargetActions
5/29/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2016OppenheimerInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2015Raymond JamesInitiated CoverageOutperform$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/14/2015Jefferies GroupReiterated RatingBuy$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2014Cowen and CompanyInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Neuroderm Ltd (NASDAQ:NDRM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/26/2016Q1($0.35)($0.25)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/31/2016Q4($0.29)$0.31ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2015Q315($0.34)($0.49)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.20)($0.34)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/27/2015Q115($0.28)($0.09)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/2/2015($0.35)($2.55)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Neuroderm Ltd (NASDAQ:NDRM)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.29)($0.29)($0.29)
Q2 20162($0.40)($0.34)($0.37)
Q3 20162($0.40)($0.36)($0.38)
Q4 20161($0.37)($0.37)($0.37)
(Data provided by Zacks Investment Research)
Dividend History for Neuroderm Ltd (NASDAQ:NDRM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Neuroderm Ltd (NASDAQ:NDRM)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Neuroderm Ltd (NASDAQ:NDRM)
DateHeadline
06/28/16 10:16 AMNeuroDerm Announces ND0612H Achieves Comparable Pharmacokinetics to DUODOPA® in Head-To-Head Pilot PK Comparison Trial
06/27/16 05:18 PMNext Weeks Broker Price Targets For NeuroDerm Ltd. (NDRM) - Fiscal Standard
06/25/16 04:58 PMBrokers Issue Average Price Target Of 27.50 On NeuroDerm Ltd. (NDRM) - Fiscal Standard
06/25/16 04:58 PMNew Broker Ratings For NeuroDerm Ltd. (NDRM) - FTSE News
06/24/16 05:35 PMNeuroDerm Added to Russell Global Index - [GlobeNewswire] - REHOVOT, Israel, June 24, 2016-- NeuroDerm Ltd., a clinical-stage pharmaceutical company developing drugs for central nervous system diseases, today announced that the company has been selected to join ...
06/23/16 05:54 PMNeuroDerm Ltd. (NasdaqGM:NDRM) Stock Momentum at Critical Inflection Point - CML News
06/23/16 08:15 AMNeuroDerm Presents Three Posters at the 20th International Congress of Parkinson’s Disease and Movement Disorders - [GlobeNewswire] - REHOVOT, Israel, June 23, 2016-- NeuroDerm Ltd., a clinical-stage pharmaceutical company developing drugs for central nervous system diseases, today presented pre-clinical data investigating ND0701, its ...
06/20/16 07:02 AMThis Weeks Broker Views For NeuroDerm Ltd. (NDRM) - Fiscal Standard
06/16/16 09:39 AMNeuroDerm to Present Design of the First Clinical Efficacy Study of ND0612H and Other Clinical Data at the 20th International Congress of…
06/16/16 09:39 AMNeuroDerm to present trial data at Parkinson’s conference
06/16/16 09:39 AMNeuroDerm to Present Design of the First Clinical Efficacy Study of ND0612H and Other Clinical Data
06/16/16 06:00 AMNeuroDerm to Present Design of the First Clinical Efficacy Study of ND0612H and Other Clinical Data at the 20th International Congress of Parkinson’s Disease and Movement Disorders - [GlobeNewswire] - -Clinical Trial Evaluating Efficacy, Safety, Tolerability and Pharmacokinetics of Two Dosing Regimens of ND0612 Compared With Oral Standard of Care Treatment in Patients With Advanced Parkinson’ s Disease-. ...
06/08/16 05:49 PMNEURODERM LTD. (NASDAQ:NDRM) Financial Condition Compared to S&P 500 - CML News
06/07/16 08:03 AMNeuroDerm (NDRM) Looks Good: Stock Adds 5.1% in Session
06/03/16 08:14 AMRevenue Update on Neuroderm Ltd(NASDAQ:NDRM) - Trade Calls - Revenue Update on Neuroderm Ltd(NASDAQ:NDRM)Trade CallsNeuroderm Ltd(NASDAQ:NDRM) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 26, 2016. Earnings per share were $-0.25. Analysts had estimated an EPS of $-0.35. Neuroderm Ltd (NDRM) ...Stock Review and Earnings Check on NeuroDerm Ltd. (NASDAQ:NDRM)HNNNeuroDerm Ltd. (NASDAQ:NDRM) Stock Update & EstimatesStock Tick Tockall 4 news articles »
06/02/16 05:46 PMNeuroDerm Ltd. (NASDAQ:NDRM) Stock Update & Estimates - Stock Tick Tock - NeuroDerm Ltd. (NASDAQ:NDRM) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting NeuroDerm Ltd. (NASDAQ:NDRM) to post earnings of $-0.34 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued around ...and more »
06/02/16 05:46 PMStock Review and Earnings Check on NeuroDerm Ltd. (NASDAQ:NDRM) - HNN - Stock Review and Earnings Check on NeuroDerm Ltd. (NASDAQ:NDRM)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting NeuroDerm Ltd. (NASDAQ:NDRM) ...and more »
06/02/16 05:46 PMBroker Watchlist: NeuroDerm Ltd. (NDRM) - Share Trading News - Broker Watchlist: NeuroDerm Ltd. (NDRM)Share Trading News12/10/2014 – Cowen began new coverage on NeuroDerm Ltd. giving the company a “outperform” rating. They now have a USD 30 price target on the stock. The share price of NeuroDerm Ltd. (NDRM) was down -0.86% during the last trading session, with a ...
06/02/16 11:59 AMNeuroDerm Ltd. :NDRM-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 -
05/31/16 01:11 PMNeuroDerm CEO to Present at Jefferies 2016 Healthcare Conference on June 7 - [GlobeNewswire] - REHOVOT, Israel, May 31, 2016-- NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system diseases, today announced that CEO Oded S. Lieberman, PhD will present ...
05/31/16 09:24 AMShare Rating Focus on NeuroDerm Ltd. (NASDAQ:NDRM) - HNN - Share Rating Focus on NeuroDerm Ltd. (NASDAQ:NDRM)HNNPresently, Wall Street analysts have given a consensus stock rating of 1.2 on shares of NeuroDerm Ltd. (NASDAQ:NDRM). Covering analysts will typically provide Buy, Sell, or Hold recommendations based on extensive research. This consensus number is ...and more »
05/30/16 10:03 PMNeuroderm Ltd (NDRM) Rating Reiterated by Roth Capital - Let Me Know About This - Neuroderm Ltd (NDRM) Rating Reiterated by Roth CapitalLet Me Know About ThisNeuroderm logo Neuroderm Ltd (NASDAQ:NDRM)'s stock had its “buy” rating reiterated by equities researchers at Roth Capital in a research report issued to clients and investors on Sunday. Several other analysts also recently commented on the company.NeuroDerm Ltd. (NDRM) Broker Price Targets For The Coming WeekShare Trading NewsWere Analysts Bearish Neuroderm Ltd (NASDAQ:NDRM) This Week?HNNall 3 news articles »
05/30/16 11:40 AMNeuroDerm Ltd. (NDRM) Broker Price Targets For The Coming Week - Share Trading News - NeuroDerm Ltd. (NDRM) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of NeuroDerm Ltd. (NDRM). The latest reports which are currently in issue on Monday 30th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts ...and more »
05/28/16 10:02 AMEarnings Review and Stock Rundown for NeuroDerm Ltd. (NASDAQ:NDRM) - Wall Street Hints and News - Earnings Review and Stock Rundown for NeuroDerm Ltd. (NASDAQ:NDRM)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting NeuroDerm Ltd. (NASDAQ:NDRM) to post ...and more »
05/28/16 10:02 AMNeuroderm Ltd (NASDAQ:NDRM) Could Be About To Enter The Multi-Billion Dollar Parkinson's Space - Market Exclusive - Market ExclusiveNeuroderm Ltd (NASDAQ:NDRM) Could Be About To Enter The Multi-Billion Dollar Parkinson's SpaceMarket ExclusiveNeuroderm Ltd (NASDAQ:NDRM) just gave us un update on its pipeline, and two elements in particular stood out as being potential drivers of near term volatility. The first, topline from a pharmacokinetic dose finding trial out of Europe – phase II – in ...
05/26/16 10:11 AMNeuroDerm reports 1Q loss - REHOVOT, Israel (AP) _ NeuroDerm Ltd. (NDRM) on Thursday reported a loss of $5.4 million in its first quarter. The Rehovot, Israel-based company said it had a loss of 25 cents per share. The results exceeded Wall Street expectations. The average estimate ...
05/26/16 06:41 AM7:41 am NeuroDerm reports Q1 results -
05/26/16 06:33 AMNeuroDerm Announces First Quarter 2016 Financial Results - [GlobeNewswire] - REHOVOT, Israel, May 26, 2016-- NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system diseases, today announced financial results for the first quarter ended ...
05/26/16 06:07 AMQ1 2016 Neuroderm Ltd Earnings Release - Before Market Open -
05/17/16 06:00 AMNeuroDerm to Host First Quarter 2016 Financial Results Conference Call on May 26, 2016 - [GlobeNewswire] - REHOVOT, Israel, May 17, 2016-- NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system diseases, today announced that it will report financial results for the ...
05/09/16 06:00 AMNeuroDerm Announces Patient Enrollment in Long-Term Safety Trial of ND0612 for Parkinson’s Disease - [GlobeNewswire] - REHOVOT, Israel, May 09, 2016-- NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system disorders, today announced the start of patient enrollment in a long-term ...
05/05/16 09:14 AMNeuroDerm Announces 2016 Annual General Meeting of Shareholders - [GlobeNewswire] - REHOVOT, Israel, May 05, 2016-- NeuroDerm Ltd., a clinical-stage pharmaceutical company developing drugs for central nervous system diseases, today announced that it will hold its 2016 Annual General Meeting ...
04/22/16 09:47 AMNeuroDerm Reveals Removal Of Import Alert By FDA On Infusion Pumps -
04/22/16 08:31 AMNeuroDerm Announces Removal of FDA Import Alert of Infusion Pumps Used in ND0612 Clinical Trials - [GlobeNewswire] - REHOVOT, Israel, April 22, 2016-- NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system diseases, today announced that the Company has been informed by Canè ...
04/05/16 06:00 AMNeuroDerm Parkinson’s Disease Clinical Data Selected for Two Oral Presentations at the American Academy of Neurology 68th Annual Meeting - [GlobeNewswire] - -An Encore Presentation on ND0612 Will be Given at the Invited Science: Movement Disorders Session Following the Identification of ND0612 Stable Levodopa Plasma Levels as a Critical Advance in the Field ...
04/01/16 11:40 AMEdited Transcript of NDRM earnings conference call or presentation 31-Mar-16 12:30pm GMT -
03/31/16 06:07 AMQ4 2015 Neuroderm Ltd Earnings Release - Before Market Open -
03/31/16 06:00 AMNeuroDerm Announces Fourth Quarter and Full Year 2015 Financial Results and Provides a Corporate Update - [GlobeNewswire] - REHOVOT, Israel, March 31, 2016-- NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system diseases, today announced financial results for the fourth quarter ...
03/22/16 06:00 AMNeuroDerm to Host Fourth Quarter and 2015 Fiscal Year Financial Results Conference Call on March 31, 2016 - [GlobeNewswire] - REHOVOT, Israel, March 22, 2016-- NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system diseases, today announced that it will report financial results for ...
02/26/16 01:01 PMNeuroderm Limited Ord (NASDAQ:NDRM) Shorted Shares Increased 0.53% After Market Selling - Franklin Independent - Neuroderm Limited Ord (NASDAQ:NDRM) Shorted Shares Increased 0.53% After Market SellingFranklin IndependentThe stock of Neuroderm Limited Ord (NASDAQ:NDRM) registered an increase of 0.53% in short interest. NDRM's total short interest was 1.13 million shares in February as published by FINRA. Its up 0.53% from 1.12 million shares, reported previously.
02/26/16 01:01 PMHow Analysts Feel About Neuroderm Ltd (NASDAQ:NDRM)? - Business Standard Tribune - How Analysts Feel About Neuroderm Ltd (NASDAQ:NDRM)?Business Standard TribuneOut of 4 analysts covering NeuroDerm (NASDAQ:NDRM), 5 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. NeuroDerm was the topic in 7 analyst reports since August 6, 2015 according to StockzIntelligence Inc. Below is a list of ...
02/07/16 01:44 PMRecent Broker Updates On NeuroDerm Ltd. (NDRM) - Risers & Fallers - Recent Broker Updates On NeuroDerm Ltd. (NDRM)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of NeuroDerm Ltd. (NDRM). The latest broker reports which are currently outstanding on Friday 5th February state 2 analysts have a rating of “strong buy”, 3 analysts “buy”, ...
02/03/16 01:42 PMCan Shares of NeuroDerm Ltd. (NASDAQ:NDRM) hit $30? - Stocks Daily - Can Shares of NeuroDerm Ltd. (NASDAQ:NDRM) hit $30?Stocks DailyAs per Zacks, NeuroDerm Ltd. (NASDAQ:NDRM) stock holds a bullish price target of $30. The brokerages listed in Zacks poll have collectively set a price target of $27.5 on firm's stock. This forecast is the average of the recommendations of 5 brokerages.and more »
02/01/16 01:39 PMCompany Shares of NeuroDerm Ltd. (NASDAQ:NDRM) Drops by -0.59% - Bull Report - Company Shares of NeuroDerm Ltd. (NASDAQ:NDRM) Drops by -0.59%Bull ReportNeuroDerm Ltd. (NASDAQ:NDRM) has lost 0.59% during the past week and dropped 20.82% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 2.3%. NeuroDerm Ltd. (NASDAQ:NDRM) has ...
01/30/16 01:20 PMEarnings Surprise in Focus: NeuroDerm Ltd. (NASDAQ:NDRM) - Investor Newswire - Earnings Surprise in Focus: NeuroDerm Ltd. (NASDAQ:NDRM)Investor NewswireFor the most recent quarter, NeuroDerm Ltd. (NASDAQ:NDRM) reported earnings per share of $-0.07 for the fiscal period ending on 2015-09-30, an earnings surprise factor of 79.41%. The actual number was $0.27 away from the brokerage firm consensus ...and more »
01/29/16 01:37 PMNeuroDerm Ltd. (NASDAQ:NDRM) Short Interest Update - The Daily Rover - NeuroDerm Ltd. (NASDAQ:NDRM) Short Interest UpdateThe Daily RoverNeuroDerm Ltd. (NASDAQ:NDRM) ensharesed a rise of 31.7% or 269,538 shares in the short positions. The number escalated from 851,566 on December 31,2015 to 1,121,104 on January 15,2016. The final interest is 11.1% of the floated stock. The days to ...
01/25/16 10:50 AM13G Filing: Scopia Capital and Neuroderm Ltd (NDRM) -
01/18/16 07:04 PMAnalysts Issue Earnings Forecast For NeuroDerm Ltd. (NASDAQ:NDRM) - Investor Newswire - Analysts Issue Earnings Forecast For NeuroDerm Ltd. (NASDAQ:NDRM)Investor NewswireAccording to analysts surveyed by Zacks Research, NeuroDerm Ltd. (NASDAQ:NDRM) is expected to post earnings of $-0.44 per share for its most recent quarter. The company is set to release its earnings around 2016-04-07. Since the same set of brokers is ...and more »
11/17/15 06:45 AMWhere Opportunity is Found – Research on Ashford Hospitality Prime, NEURODERM, NN Inc. and Roadrunner Transportation Systems - [Accesswire] - NEW YORK, NY / ACCESSWIRE / November 17, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Ashford Hospitality ...
11/12/15 03:05 PMNeuroDerm CEO to Present at Upcoming Investor Conferences - [GlobeNewswire] - REHOVOT, Israel -- NeuroDerm Ltd. , a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the ...
About Neuroderm Ltd

Neuroderm Ltd logoNeuroDerm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson's disease, as well as other CNS diseases. The Company is developing ND0612H for the treatment of patients suffering from severe Parkinson's disease; ND0612L for the treatment of patients at the moderate stage of Parkinson's disease that can no longer control motor complications with oral levodopa, and ND0680 for the treatment of a small subset of severe Parkinson's disease patients, whose symptoms have advanced to a severe stage, requiring even higher doses of LD/CD than ND0612H is designed to provide. The Company has also designed ND0701, an apomorphine-based product candidate that offers an alternative to the continuously administered apomorphine product, and ND0801, to treat cognition disorders associated with CNS diseases, such as ADD/ADHD, Alzheimer's disease and schizophrenia.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NDRM
  • CUSIP:
Key Metrics:
  • Previous Close: $15.72
  • 50 Day Moving Average: $17.34
  • 200 Day Moving Average: $15.40
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $346.61M
  • Current Quarter EPS Consensus Estimate: $-1.52 EPS
Additional Links:
Neuroderm Ltd (NASDAQ:NDRM) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha